CONTEXT: Numerous predictive and prognostic tools have recently been developed for risk stratification of prostate cancer (PCa) patients who are candidates for or have been treated with radical prostatectomy (RP). OBJECTIVE: To critically review the currently available predictive and prognostic tools for RP patients and to describe the criteria that should be applied in selecting the most accurate and appropriate tool for a given clinical scenario. EVIDENCE ACQUISITION: A review of the literature was performed using the Medline, Scopus, and Web of Science databases. Relevant reports published between 1996 and January 2010 identified using the keywords prostate cancer, radical prostatectomy, predictive tools, predictive models, and nomograms were critically reviewed and summarised. EVIDENCE SYNTHESIS: We identified 16 predictive and 22 prognostic validated tools that address a variety of end points related to RP. The majority of tools are prediction models, while a few consist of risk-stratification schemes. Regardless of their format, the tools can be distinguished as preoperative or postoperative. Preoperative tools focus on either predicting pathologic tumour characteristics or assessing the probability of biochemical recurrence (BCR) after RP. Postoperative tools focus on cancer control outcomes (BCR, metastatic progression, PCa-specific mortality [PCSM], overall mortality). Finally, a novel category of tools focuses on functional outcomes. Prediction tools have shown better performance in outcome prediction than the opinions of expert clinicians. The use of these tools in clinical decision-making provides more accurate and highly reproducible estimates of the outcome of interest. Efforts are still needed to improve the available tools' accuracy and to provide more evidence to further justify their routine use in clinical practice. In addition, prediction tools should be externally validated in independent cohorts before they are applied to different patient populations. CONCLUSIONS: Predictive and prognostic tools represent valuable aids that are meant to consistently and accurately provide most evidence-based estimates of the end points of interest. More accurate, flexible, and easily accessible tools are needed to simplify the practical task of prediction.
CONTEXT: Numerous predictive and prognostic tools have recently been developed for risk stratification of prostate cancer (PCa) patients who are candidates for or have been treated with radical prostatectomy (RP). OBJECTIVE: To critically review the currently available predictive and prognostic tools for RP patients and to describe the criteria that should be applied in selecting the most accurate and appropriate tool for a given clinical scenario. EVIDENCE ACQUISITION: A review of the literature was performed using the Medline, Scopus, and Web of Science databases. Relevant reports published between 1996 and January 2010 identified using the keywords prostate cancer, radical prostatectomy, predictive tools, predictive models, and nomograms were critically reviewed and summarised. EVIDENCE SYNTHESIS: We identified 16 predictive and 22 prognostic validated tools that address a variety of end points related to RP. The majority of tools are prediction models, while a few consist of risk-stratification schemes. Regardless of their format, the tools can be distinguished as preoperative or postoperative. Preoperative tools focus on either predicting pathologic tumour characteristics or assessing the probability of biochemical recurrence (BCR) after RP. Postoperative tools focus on cancer control outcomes (BCR, metastatic progression, PCa-specific mortality [PCSM], overall mortality). Finally, a novel category of tools focuses on functional outcomes. Prediction tools have shown better performance in outcome prediction than the opinions of expert clinicians. The use of these tools in clinical decision-making provides more accurate and highly reproducible estimates of the outcome of interest. Efforts are still needed to improve the available tools' accuracy and to provide more evidence to further justify their routine use in clinical practice. In addition, prediction tools should be externally validated in independent cohorts before they are applied to different patient populations. CONCLUSIONS: Predictive and prognostic tools represent valuable aids that are meant to consistently and accurately provide most evidence-based estimates of the end points of interest. More accurate, flexible, and easily accessible tools are needed to simplify the practical task of prediction.
Authors: Umberto Capitanio; Pierre I Karakiewicz; Claudio Jeldres; Alberto Briganti; Andrea Gallina; Nazareno Suardi; Andrea Cestari; Giorgio Guazzoni; Andrea Salonia; Francesco Montorsi Journal: Int J Urol Date: 2009-03-26 Impact factor: 3.369
Authors: Naeem Bhojani; Laurent Salomon; Umberto Capitanio; Nazareno Suardi; Shahrokh F Shariat; Claudio Jeldres; Laurent Zini; Daniel Pharand; François Péloquin; Philippe Arjane; Claude C Abbou; Alexandre De La Taille; Francesco Montorsi; Pierre I Karakiewicz Journal: Int J Radiat Oncol Biol Phys Date: 2008-11-10 Impact factor: 7.038
Authors: N Bhojani; S Ahyai; M Graefen; U Capitanio; N Suardi; S F Shariat; C Jeldres; A Erbersdobler; T Schlomm; A Haese; T Steuber; H Heinzer; F Montorsi; H Huland; P I Karakiewicz Journal: Eur J Surg Oncol Date: 2008-09-10 Impact factor: 4.424
Authors: Christopher R Porter; Nazareno Suardi; Koichi Kodama; Umberto Capitanio; Robert P Gibbons; Roy Correa; Claudio Jeldres; Paul Perrotte; Francesco Montorsi; Pierre I Karakiewicz Journal: Int J Urol Date: 2008-07-24 Impact factor: 3.369
Authors: Jochen Walz; Felix K-H Chun; Eric A Klein; Alwyn Reuther; Fred Saad; Markus Graefen; Hartwig Huland; Pierre I Karakiewicz Journal: J Urol Date: 2008-12-13 Impact factor: 7.450
Authors: Kevin C Zorn; Umberto Capitanio; Claudio Jeldres; Philippe Arjane; Paul Perrotte; Shahrokh F Shariat; David I Lee; Arieh L Shalhav; Gregory P Zagaja; Sergey A Shikanov; Ofer N Gofrit; Alan E Thong; David M Albala; Leon Sun; Pierre I Karakiewicz Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-19 Impact factor: 7.038
Authors: Umberto Capitanio; Pierre I Karakiewicz; Luc Valiquette; Paul Perrotte; Claudio Jeldres; Alberto Briganti; Andrea Gallina; Nazareno Suardi; Andrea Cestari; Giorgio Guazzoni; Andrea Salonia; Francesco Montorsi Journal: Urology Date: 2009-02-04 Impact factor: 2.649
Authors: Jose López-Torrecilla; Anna Boladeras; María Angeles Cabeza; Almudena Zapatero; Josep Jove; Luis M Esteban; Ivan Henriquez; Manuel Casaña; Carmen González-San Segundo; Antonio Gómez-Caamaño; Jose Luis Mengual; Asunción Hervás; Julia Luisa Muñoz; Gerardo Sanz Journal: Strahlenther Onkol Date: 2015-07-09 Impact factor: 3.621
Authors: Haley Hieronymus; Nikolaus Schultz; Anuradha Gopalan; Brett S Carver; Matthew T Chang; Yonghong Xiao; Adriana Heguy; Kety Huberman; Melanie Bernstein; Melissa Assel; Rajmohan Murali; Andrew Vickers; Peter T Scardino; Chris Sander; Victor Reuter; Barry S Taylor; Charles L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2014-07-14 Impact factor: 11.205
Authors: Bassem R Haddad; Andrew Erickson; Vindhya Udhane; Peter S LaViolette; Janice D Rone; Markku A Kallajoki; William A See; Antti Rannikko; Tuomas Mirtti; Marja T Nevalainen Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-07-10 Impact factor: 4.254
Authors: Stepan Vesely; Ladislav Jarolim; Marek Schmidt; Ivo Minarik; Pavel Dusek; Marko Babjuk Journal: World J Urol Date: 2012-06-10 Impact factor: 4.226